Navigation Links
OHSU Cancer Institute researcher develops test for targeted therapy in acute myeloid leukemia
Date:12/10/2007

ATLANTA Oregon Health & Science University Cancer Institute researcher Jeff Tyner, Ph.D., has created a way to identify proteins that are candidates for targeted therapy in acute myeloid leukemia using an assay that yields results in just four days. This research will be presented at the American Society of Hematology annual meeting in Atlanta, on Monday, Dec. 10, at 8:15 a.m.

This functional assay, called RAPID, because it rapidly delivers the information, has the capability of telling researchers which actual proteins from the tyrosine kinase family are contributing to an individual patients cancer.

If you know what protein is driving the cancer, you have the ability to target that protein and stop it. With this knowledge it may be possible to match targeted drugs with the appropriate patient. It may also be possible to identify mechanisms as to why certain leukemias respond well to therapy and why others may not. The real novelty of our work is that we have performed this assay directly on patient samples. It gets us one step closer to the clinic and personalized medicine, said Tyner, a fellow in hematology/ medical oncology, OHSU School of Medicine.

This research has several important aspects. First, it will enable researches to more quickly compile a database of mutant genes that cause cancer. That will enable better diagnosis in the future using DNA sequencing technology. Second, it is possible that this technology may, in the future, be adapted for direct clinical use for diagnostic purposes. In this manner, the RAPID screen could be run on a patients malignant cells, and the appropriate drug could then be determined to treat that patient. Thirdly, the assay can be completed in just four days, whereas previous technologies could take months to years to yield similar information.

Tyner came about his discovery as many scientists do: trial and error and then success.

We were initially screening for these targets by doing large-scale DNA sequencing, looking for mutations. This strategy was not as successful as we had hoped, so we decided that an assay that could functionally screen cells and give us some idea based on what killed cells and what didnt kill cells would be a better place to start. We could then work backward to find the actual mutation underlying that phenotype. RNAi (the name of the technology we use) seemed an ideal platform for this because it allows you to knock down the expression of individual genes, Tyner said.


'/>"/>

Contact: Christine Decker
deckerch@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... today announced its strategic partnership with Connance, a healthcare industry leader providing ... companies’ proven, proprietary technology combine to provide health systems, hospitals and ambulatory ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/24/2016)... HILL, N.C. , June 24, 2016 /PRNewswire/ ... healthcare decisions and regulators/payers have placed more emphasis ... new environment, patient support programs in the pharmaceutical ... for patients, medications. Consequently, pharmaceutical companies are focusing ... ensure they are providing products and services that ...
(Date:6/24/2016)...   Bay Area Lyme Foundation , collaborating ... for Tick Borne Illness , Harvard Medical School ... Medicine, University of California, Berkeley, and the Veterans ... finalists of Lyme Innovation , the first ... scientists, clinicians, researchers, entrepreneurs, and investors from several ...
Breaking Medicine Technology: